Banco Santander S.A. Acquires 29,997 Shares of Johnson & Johnson (NYSE:JNJ)

Banco Santander S.A. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 118.8% in the second quarter, Holdings Channel reports. The firm owned 55,256 shares of the company’s stock after purchasing an additional 29,997 shares during the period. Banco Santander S.A.’s holdings in Johnson & Johnson were worth $8,076,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. GUNN & Co INVESTMENT MANAGEMENT INC. raised its stake in Johnson & Johnson by 1,194.9% in the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock valued at $37,190,000 after acquiring an additional 218,949 shares during the period. Wynn Capital LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,910,000. Capital Advisors Ltd. LLC grew its position in shares of Johnson & Johnson by 6.4% in the fourth quarter. Capital Advisors Ltd. LLC now owns 3,454 shares of the company’s stock valued at $541,000 after purchasing an additional 209 shares in the last quarter. Atria Wealth Solutions Inc. lifted its holdings in Johnson & Johnson by 2.8% during the 4th quarter. Atria Wealth Solutions Inc. now owns 162,847 shares of the company’s stock worth $25,525,000 after purchasing an additional 4,497 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in shares of Johnson & Johnson by 2.4% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 56,732 shares of the company’s stock valued at $8,892,000 after buying an additional 1,343 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.1 %

Shares of JNJ stock traded up $0.22 during trading hours on Friday, reaching $164.45. The company’s stock had a trading volume of 1,177,523 shares, compared to its average volume of 7,233,902. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a one year low of $143.13 and a one year high of $165.83. The stock has a market capitalization of $395.78 billion, a P/E ratio of 10.25, a P/E/G ratio of 2.63 and a beta of 0.52. The firm’s fifty day simple moving average is $155.01 and its 200 day simple moving average is $153.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the previous year, the firm earned $2.80 EPS. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a $1.24 dividend. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. Morgan Stanley upped their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Sanford C. Bernstein raised their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. The Goldman Sachs Group dropped their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.